Human MnSOD and Cancer Research
From Proteopedia
Line 15: | Line 15: | ||
== Diseases/Research == | == Diseases/Research == | ||
- | Human Manganese Superoxide Dismutase has been recently studied due to its role in malignancy in cancer. It was shown that when MnSOD is overexpressed so that there is a large amount of MnSOD present in the cancerous cells, there was a decrease in the multiplicity of those cells (UVB). Moreover, it was also shown in a “...mouse skin keratinocyte model…” that overexpression of MnSOD can also protect mitochondrial proteins from UVB radiation (UVB). When MnSOD was deactivated by UVB radiation, which is caused by the disruption of active site | + | Human Manganese Superoxide Dismutase has been recently studied due to its role in malignancy in cancer. It was shown that when MnSOD is overexpressed so that there is a large amount of MnSOD present in the cancerous cells, there was a decrease in the multiplicity of those cells (UVB). Moreover, it was also shown in a “...mouse skin keratinocyte model…” that overexpression of MnSOD can also protect mitochondrial proteins from UVB radiation (UVB). When MnSOD was deactivated by UVB radiation, which is caused by the disruption of active site Tyr34 residues via nitration by the formation of Peroxynitrite (Dhar et al). Peroxynitrite is created by the combination of Nitric oxide and Superoxide. The effect of this nitration can have various effects on function depending upon which residues are nitrated (Dhar et al). By altering the tyrosine residues peroxynitrite decreases the activity of MnSOD. The deactivation of MnSOD showed that the cell increased its ability to undergo autophagy via signaling pathways that depend on the relative level of ROS in the cell, this allows the cell to stop the buildup of defective mitochondria (Dhar et al). If the level of ROS and defective mitochondria is lethal then the cell will undergo apoptosis (Dhar et al). If MnSOD is deactivated then we will have an increase of ROS in the cell, this will cause oxidative stress. It has been shown that this oxidative stress promotes tumor formation and cell division (Church et al). The Human Manganese SOD gene was located to be on chromosome six, this area of DNA was found to be missing in cases of malignant melanoma (Church et al). This shows that MnSOD plays a big role by degrading ROS as well as a role in tumor growth/malignancy. This characteristic of MnSOD is why MnSOD is being targeted in recent research. |
SODs, in general, have also been used in response to the side effects of radiation therapy. While undergoing radiation therapy or chemotherapy the patient’s cells become quite toxic due to an increase in the amount of ROS, this occurs in both tumor cells and normal tissue. Although its greater in cancer cells there is still considerably toxicity in regular human tissue (“Utilizing Superoxide Dismutase”). One of the drugs that are being used is GC4419 which is a class of Mn (II) SOD, it is very specific for the removal of superoxide and no other ROS (“Utilizing Superoxide Dismutase”). The reason this medication is thought to be protective of normal tissue is that in the differences in oxidative metabolism between the two types of cells (“Utilizing Superoxide Dismutase”). This toxicity has been found to be decreased by Superoxide dismutase which leads to improved patient recovery by aiding in the removal of ROS after treatment. Nevertheless, SODs have been shown in this type of therapy to aid in the treatment of other side effects like Mucositis which are a result of the chemoradiation therapy (“Utilizing Superoxide Dismutase”). The shows the use of MnSOD in therapeutic strategies can lead to positive results for the patient. Using MnSOD to treat certain patients has shown to be quite effective with very promising results, however, the enzyme itself has a very short half-life of around six minutes (Azadmanesh). One of the ways they can increase the half-life is by using liposomal delivery which increases the half-life to four hours, although it’s a large increase, the downfall is that the MnSOD drugs must be administered regularly and often (Azadmanesh). | SODs, in general, have also been used in response to the side effects of radiation therapy. While undergoing radiation therapy or chemotherapy the patient’s cells become quite toxic due to an increase in the amount of ROS, this occurs in both tumor cells and normal tissue. Although its greater in cancer cells there is still considerably toxicity in regular human tissue (“Utilizing Superoxide Dismutase”). One of the drugs that are being used is GC4419 which is a class of Mn (II) SOD, it is very specific for the removal of superoxide and no other ROS (“Utilizing Superoxide Dismutase”). The reason this medication is thought to be protective of normal tissue is that in the differences in oxidative metabolism between the two types of cells (“Utilizing Superoxide Dismutase”). This toxicity has been found to be decreased by Superoxide dismutase which leads to improved patient recovery by aiding in the removal of ROS after treatment. Nevertheless, SODs have been shown in this type of therapy to aid in the treatment of other side effects like Mucositis which are a result of the chemoradiation therapy (“Utilizing Superoxide Dismutase”). The shows the use of MnSOD in therapeutic strategies can lead to positive results for the patient. Using MnSOD to treat certain patients has shown to be quite effective with very promising results, however, the enzyme itself has a very short half-life of around six minutes (Azadmanesh). One of the ways they can increase the half-life is by using liposomal delivery which increases the half-life to four hours, although it’s a large increase, the downfall is that the MnSOD drugs must be administered regularly and often (Azadmanesh). |
Revision as of 15:29, 22 April 2019
Your Heading Here (maybe something like 'Structure')
|
References
Azadmanesh, J.; Borgstahl, G.E.O. A Review of the Catalytic Mechanism of Human Manganese Superoxide Dismutase. Antioxidants 2018, 7, 25.
Borgstahl et al. “The structure of a human mitochondrial superoxide dismutase reveals a novel tetrameric interface of two 4-helix bundles.” Cell, Vol. 71, 1 Oct. 2, 1992, 0092-8674(92)90270-M
Church et al. “Increased Manganese Superoxide Dismutase Expression Suppresses the Malignant Phenotype of Human Melanoma Cells.” Pnas.org.
Dhar et al, Sanjit. “UVB-Induced Inactivation of Manganese-Containing Superoxide Dismutase Promotes Mitophagy via ROS-Mediated mTORC2 Pathway Activation.” Jbc.org, 2019, www.jbc.org/content/early/2019/03/11/jbc.RA118.006595.full.pdf.
“Utilizing Superoxide Dismutase Mimetics to Enhance Radiation Therapy Response While Protecting Normal Tissues.” Seminars in Radiation Oncology, W.B. Saunders, 17 Dec. 2018, www.sciencedirect.com/science/article/pii/S1053429618300869.
RCSB Protein Data Bank. “Homepage.” RCSB PDB, www.rcsb.org/.
Turrens, Julio F. “Mitochondrial Formation of Reactive Oxygen Species.” The Journal of Physiology, John Wiley & Sons, Ltd (10.1111), 16 July 2004, physoc.onlinelibrary.wiley.com/doi/full/10.1111/j.1469-7793.2003.00335.x.
Hernández‐López, Reyniel, et al. “Sirtuin 3 Silencing Improves Oxaliplatin Efficacy through Acetylation of MnSOD in Colon Cancer.” Journal of Cellular Physiology, John Wiley & Sons, Ltd, 6 Mar. 2018, onlinelibrary.wiley.com/doi/abs/10.1002/jcp.26443.
Lu, J, et al. “A Small Molecule Activator of SIRT3 Promotes Deacetylation and Activation of Manganese Superoxide Dismutase.” Free Radical Biology & Medicine., U.S. National Library of Medicine, Nov. 2017, www.ncbi.nlm.nih.gov/pubmed/?term=28711502.